EFSA Confirmed Beta-NMN Is Safe. Brands Still Can’t Sell It in the EU Without Approval
EFSA confirmed beta-NMN is safe at 300mg/day in May 2026, but EU Novel Food authorization is still needed before NMN supplements can be marketed in Europe.
EFSA’s Positive Safety Opinion on NMN Opens the EU Authorization Path
EFSA published a positive safety opinion on beta-NMN on May 13, 2026, confirming 300mg per day safe for the general adult population and formally opening the EU Novel Food authorization pathway. For US sports nutrition brands, this is the signal that EU market access for NMN is now a near-term target, not a regulatory unknown. EU authorization typically follows a positive EFSA opinion within five to seven months, putting the practical entry window at Q4 2026 to Q1 2027.